{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:54:56Z","timestamp":1792007696875,"version":"4.4.0"},"reference-count":28,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T00:00:00Z","timestamp":1519257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The use of rifampicin for cholestatic pruritus is accompanied by concerns over safety, but the availability of real\u2010world prescribing data is relatively limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>We sought to describe the rate and characteristics of rifampicin\u2010induced hepatitis in a mixed aetiology cohort of patients with established liver disease and cholestatic pruritus.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Retrospective review of records for out\u2010patients commenced on rifampicin for pruritus 2012\u20102016 inclusive. Rifampicin\u2010induced hepatitis was recorded where alanine aminotransferase activity (<jats:styled-content style=\"fixed-case\">ALT<\/jats:styled-content>) increased to both \u22655 \u00d7 baseline and \u22655 \u00d7 upper limit of normal (<jats:styled-content style=\"fixed-case\">ULN<\/jats:styled-content>), or to both \u22653 \u00d7 baseline and \u22653 \u00d7 <jats:styled-content style=\"fixed-case\">ULN<\/jats:styled-content> with concurrent elevation in serum bilirubin to \u22652 \u00d7 baseline and \u22652 \u00d7 <jats:styled-content style=\"fixed-case\">ULN<\/jats:styled-content>, in addition to a Roussel\u2010Uclaf Causality Assessment Method score of \u201cprobable\u201d or \u201chighly probable\u201d for rifampicin causality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After exclusions, we reviewed 105 patients who took rifampicin for a median of 131 days. Most had primary biliary cholangitis or primary sclerosing cholangitis; 40 (38.1%) were men and median age was 44 years (<jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content>: 32\u201057). 44 (41.9%) patients had baseline serum bilirubin \u22652 \u00d7 <jats:styled-content style=\"fixed-case\">ULN<\/jats:styled-content> and 28 (26.7%) A<jats:styled-content style=\"fixed-case\">LT<\/jats:styled-content> \u22653 \u00d7 <jats:styled-content style=\"fixed-case\">ULN<\/jats:styled-content>. 5 (4.8%) developed rifampicin\u2010induced hepatitis at a median of 70(range 27\u2010130) days after drug initiation. No individual or laboratory baseline characteristics were significantly associated with subsequent development of hepatitis. All cases of hepatitis recovered after drug cessation, although one patient was hospitalised and received corticosteroids.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Given the efficacy of rifampicin for an important sub\u2010group of those with cholestatic pruritus, adult patients, including those with jaundice, can be counselled that 95% of prescriptions are safe, and where hepatitis occurs, including at long latency, drug cessation appears effective.<\/jats:p><\/jats:sec>","DOI":"10.1111\/apt.14579","type":"journal-article","created":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T05:27:53Z","timestamp":1519277273000},"page":"1213-1219","source":"Crossref","is-referenced-by-count":35,"title":["Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross\u2010disease cohort study"],"prefix":"10.1111","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0710-5644","authenticated-orcid":false,"given":"G. J.","family":"Webb","sequence":"first","affiliation":[{"name":"Birmingham Biomedical Research Centre (BRC) National Institute for Health Research (NIHR) University of Birmingham Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. R.","family":"Rahman","sequence":"additional","affiliation":[{"name":"Birmingham Biomedical Research Centre (BRC) National Institute for Health Research (NIHR) University of Birmingham Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Levy","sequence":"additional","affiliation":[{"name":"University of Miami Miami FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. M.","family":"Hirschfield","sequence":"additional","affiliation":[{"name":"Birmingham Biomedical Research Centre (BRC) National Institute for Health Research (NIHR) University of Birmingham Birmingham UK"},{"name":"Institute of Translational Medicine Birmingham Health Partners University Hospitals Birmingham NHS Trust Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,2,22]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.09.004"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)91608-5"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01300759"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(88)90442-8"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(90)90027-X"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-199004000-00012"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22906"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.022"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200510-1666ST"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0962-8479(96)90098-2"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.99.2.465"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2108091"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2006.01326.x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01200.x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.50.3.436"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(92)90335-V"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.58"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(93)90101-6"},{"key":"e_1_2_7_20_1","unstructured":"LiverTox. Rifampin.2014. Available from:https:\/\/livertox.nlm.nih.gov\/Rifampin.htm. Accessed July 14 2017."},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2014.131"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cld.365"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23577"},{"key":"e_1_2_7_24_1","first-page":"461","article-title":"Predisposing factors in hepatitis induced by isoniazid\u2010rifampin treatment of tuberculosis","volume":"118","author":"Gronhagen\u2010Riska C","year":"1978","journal-title":"Am Rev Respir Dis"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-008-9085-y"},{"key":"e_1_2_7_26_1","unstructured":"Datapharm Communications Limited. eMedicines.org.uk.SPC Rifadin 150mg Capsules.2017. Available from:http:\/\/www.medicines.org.uk\/emc\/medicine\/21221. Accessed May 2 2017."},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04158.x"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12603"},{"key":"e_1_2_7_29_1","first-page":"295","article-title":"Hepatotoxicity of antituberculous drugs","volume":"30","author":"Rao NK","year":"1982","journal-title":"J Assoc Physicians India"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.14579","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.14579","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T15:21:03Z","timestamp":1694013663000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.14579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,22]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1111\/apt.14579"],"URL":"https:\/\/doi.org\/10.1111\/apt.14579","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,22]]}}}